Syncom Formulations (India) Ltd

Syncom Formulations maintains a relatively strong liquidity position, with a current ratio of 2.59, indicating that it has more than twice the current assets to cover its current liabilities. However, the company reported negative operating cash flow of INR 59.58 million and capital expenditure of INR 81.36 million, suggesting ongoing investment in operations and infrastructure. The liquidity_fpt metric shows that the company has INR 633.83 million in cash and equivalents, but this is partially offset by INR 724.87 million in long-term debt, resulting in a net cash negative position. In terms of profitability, the company's return on equity (ROE) of 2.57% and return on assets (ROA) of 1.83% are below the industry median for pharmaceutical firms, which typically report ROE and ROA in the 5-10% range. The operating margin of 10.9% is also below the industry median of 15-20%, indicating that the company is underperforming in terms of cost control and pricing power. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification beyond India. This lack of diversification increases exposure to domestic regulatory and economic risks, particularly in a sector that is heavily influenced by government pricing policies and reimbursement frameworks. Looking ahead, the company's revenue is projected to grow by 8.5% in the current fiscal year and 6.2% in the next fiscal year, based on historical revenue trends and industry growth assumptions. However, the growth trajectory is modest compared to the industry average of 12-15%. The company's capital expenditure is expected to remain stable, with no significant new projects disclosed in recent filings. The risk assessment indicates a medium liquidity risk due to the negative net cash position and a low dilution risk, as the company has not issued new shares in the past 12 months. The key risk flag is the negative net cash position, which could limit the company's ability to fund operations or pursue growth opportunities without external financing. Recent filings and transcripts show that the company is focused on expanding its product portfolio and improving manufacturing efficiency. No major regulatory or legal issues have been disclosed in the past 12 months, and the company has not issued any public warnings about potential dilution or liquidity constraints.